

# Priority Health Medicare prior authorization form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: This request is: Medicare Part B
 Expedited request

Medicare Part D
Standard request

Your request will be expedited if you haven't gotten the prescription and Priority Health Medicare determines, or your prescriber tells us, that your life or health may be at risk by waiting.

# Ventavis<sup>®</sup> (iloprost)

Member
--------

Last Name:		First Name:	
			Gender:
	cian:		
Requesting Provider:		Prov. Phone:	Prov. Fax:
Provider NPI: Provider Signature:			
		Date:	
Product and Bil	lling Information		
New request	Continuation request		
Drug product:	<ul> <li>Ventavis 10 mcg/mL solution</li> <li>Ventavis 20 mcg/mL solution</li> </ul>	-	e):

# Prior authorization criteria

The following requirements need to be met before this drug is covered by Priority Health Medicare. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

- 1. Diagnosis of World Health Organization group 1 classification of pulmonary arterial hypertension
- 2. Prescriber must submit the patient's systolic blood pressure

## Medically accepted indication

This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either*.

- approved by the Food and Drug Administration. (That is, the Food and Drug Administration has approved the drug for the diagnosis or condition for which it is being prescribed.)
- *or* supported by certain reference books. (These reference books are the American Hospital Formulary Service Drug Information, the DRUGDEX Information System, and the USPDI or its successor.)

## **Priority Health Precertification Documentation**

## A. What condition is this drug being requested for?

- WHO Group 1 pulmonary arterial hypertension
  - WHO Group 3 pulmonary hypertension
  - ] WHO Group 5 pulmonary hypertension
- WHO Group 2 pulmonary hypertension
   WHO Group 4 pulmonary hypertension
   Other the patient's condition is:
- B. What is the patient's systolic blood pressure? \_\_\_\_\_



#### **Additional information**

The World Health Organization divides pulmonary hypertension into five groups based on the cause of the condition and its treatment options. Group 1 is called pulmonary **arterial** hypertension and groups 2-5 are called pulmonary hypertension. Below is a listing of various conditions and how they are classified by the World Health Organization.

#### Group 1 pulmonary arterial hypertension includes:

- No known cause
- Inherited
- Caused by drugs or toxins
- Connective tissues diseases
- HIV infection
- Liver disease
- Congenital heart disease
- Sickle cell disease
- Schistosomiasis
- Conditions that affect the veins and small blood vessels of the lungs

#### Group 2 pulmonary hypertension includes:

Conditions that affect the left side of the heart (e.g. mitral valve disease, long-term high blood pressure)

#### Group 3 pulmonary hypertension includes:

Lung diseases such: COPD or Interstitial lung disease

#### Group 4 pulmonary hypertension includes:

- Blood clots in the lungs
- Blood clotting disorders

#### Group 5 pulmonary hypertension includes:

- Various other conditions, including:
  - Blood disorders, such as polycythemia vera and essential thrombocythemia
  - Systemic disorders, such as sarcoidosis and vasculitis
  - Metabolic disorders, such as thyroid disease and glycogen storage disease
  - Other conditions, such as tumors that press on the pulmonary arteries and kidney disease

#### Priority Health Medicare exception request

Do you believe one or more of the prior authorization requirements should be waived?  Yes	🗌 No
If yes, you must provide a statement explaining the medical reason why the exception should be approve	əd.

#### Would Ventavis likely be the most effective option for this patient?

Yes No
If yes, please explain why: \_\_\_\_\_\_

# If the patient is currently using Ventavis, would changing the patient's current regimen likely result in adverse effects for the patient?

Yes No
If yes, please explain:

Page 2 of 2 All fields must be complete and legible for review. Your office will receive a response via fax. No changes made since 07/2013 Last reviewed 07/2019